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“clinical NEUroPROteomics of neurodegenerative diseases” (cNEUPRO) is a Speciﬁc Targeted Research Project (STREP) within
thesixth framework program of the European Commissiondedicated to the search for novel biomarker candidates for Alzheimer’s
disease and other neurodegenerative diseases. The ultimate goal of cNEUPRO is to identify one or more valid biomarker(s) in
blood and CSF applicable to support the early and diﬀerential diagnosis of dementia disorders. The consortium covers all steps
required for the discovery of novel biomarker candidates such as acquisition of high quality CSF and blood samples from relevant
patient groups and controls, analysis of body ﬂuids by various methods, and ﬁnally assay development and assay validation. Here
we report the standardized procedures for diagnosis and preanalytical sample-handling within the project, as well as the status of
the ongoing research activities and some ﬁrst results.2 International Journal of Alzheimer’s Disease
1.Introduction
The diagnosis of Alzheimer’s Disease (AD) is currently
based primarily on clinical symptoms. Whereas the sen-
sitivity of the clinical diagnosis for possible and probable
Alzheimer Dementia according to National Institute of
Neurological and Communicative Disorders and Stroke and
the Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) criteria is over 80%, its speciﬁcity is
rather low [1]. The term mild cognitive impairment (MCI)
was introduced for subjects who complain about veriﬁable
cognitive disturbances but who show a preserved general
cognitive functioning and no impairment in the activities
of daily living [2]. These patients can be further subdivided
into those with an impaired memory function (amnestic
MCI) and those whose memory is preserved but who
show disturbances of language, executive function, or visual-
spatial skills (Nonamnestic MCI) [2]. If only one of the
above-mentioned cognitive domains is impaired, patients
are called single-domain MCI; if two or more domains
are aﬀected, they are referred to as multidomain MCI.
Although the term MCI is solely descriptive and allows no
conclusion on the aetiology, the classiﬁcation allows some
prediction of the course of the disease. For amnestic MCI
patients, the risk to convert to Alzheimer’s Dementia is
10–15% per year [3]. Yet, an accurate early diagnosis in
MCI patients or even a predictive diagnosis in individuals
withoutcognitivedisturbancesisstillvirtuallyimpossible.As
there is evidence that pathological biochemical changes start
many years before the occurrence of functional symptoms,
identiﬁcation of biological markers in individuals with early-
stage dementia is the most promising way to facilitate a
predictive diagnosis [4–6].
Improving the early and predictive diagnosis of AD is
of paramount importance if, in the future, preventive and
disease-modifying therapies become available. In this regard,
enormous eﬀorts are under way. Although most therapies
failed to show eﬃcacy in Phase III trials, there are still
some promising approaches like Aβ lowering compounds,
inhibitors of inﬂammation, inhibitors of tau phosphory-
lation and aggregation, and compounds interfering with
cholesterol metabolism under investigation [7]. Although
the brain has some limited regenerative capacity, neurons
are still diﬃcult to replace [8, 9]. Therefore, it is clear
that maximal beneﬁt for the patients can be expected
when the treatment can be initiated as early as possible
in the course of the disease. Furthermore, biologically
valid and clinically accurate biomarkers may serve in the
development of novel therapeutic strategies and may pro-
vide important information in clinical trials of therapies
[10].
Well-documented biomarkers for AD in cerebrospinal
ﬂuid (CSF) include alterations in Aβ1-42, total-tau, and
phospho-tau [10]. Importantly, these particular changes are
detectable in early dementia stages as well as in individuals
with mild cognitive impairment (MCI) who are at high
risk of conversion to AD [11]. When analyzed in well-
characterized clinical samples, the measurement of Aβ1-42,
tau, and phospho-tau in cerebrospinal ﬂuid generally allows
thediagnosisofADandeventhepredictionoftheconversion
f r o mM C It oA Dw i t has p e c i ﬁ c i t ya n ds e n s i t i v i t yo fa b o u t
85% [12]. However, some report a lower sensitivity of
below 50% for single biomarkers when these biomarkers are
measured as part of a routine diagnostic test in a memory
clinic [13]. This drop in sensitivity can be explained by
the fact that in clinical practice the reference cohort is
not a group of cognitively healthy individuals but consists
of patients with other neurodegenerative and neurologic
diseases who may also have slightly elevated total-tau,
phospho-tau, or Aβ1-42 levels [13]. The application of these
markers in the diﬀerential diagnostic of neurodegenerative
diseases therefore proves to be particularly problematic
[14]. Consequently, there is a need for additional and
more sensitive CSF biomarkers for the early and diﬀerential
diagnosis of Alzheimer’s Disease.
There is the additional problem of lumbar puncture to
obtain CSF, since although the rate of complications during
a n da f t e rl u m b a rp u n c t u r ei sb e l o w2 – 4 %a n dr e s t r i c t e dt o
mild to moderate postlumbar puncture headache [15–18],
it must still be seen as invasive method for which special
precautions must be taken. Consequently, there is a pressing
need for new biomarkers in more easily accessible body-
ﬂuids such as peripheral blood.
Clinical proteomics is a fast developing ﬁeld dedicated
to the search for new biomarkers applicable to support the
clinical diagnosis [19]. At present, a number of potential
new biomarker-candidates for AD have been reported from
proteomic studies [20, 21]; unfortunately, however, the
published data is often contradictory and in many cases, a
solid reassessment by other methods and with independent
samples is required [19].
Taking this into account, the EU-project Clinical Pro-
teomics for Neurodegenerative Diseases (cNEUPRO) is not
only dedicated to the detection of potential new biomarker
candidates for neurodegenerative diseases in CSF and blood,
but also to the implementation of in-depth reassessments
and validation studies. Finally, promising biomarker can-
didates will be studied for their suitability as routine test
analytes by prototype assays.
2. cNEUPRO: The Consortium, Goals,
and Workﬂow
cNEUPRO (http://www.cneupro.eu/)i saS p e c i ﬁ cT a r g e t e d
Research Project (STREP) within the sixth framework
program of the European Commission. It started in April
2007 and is coordinated by Jens Wiltfang, University of
Duisburg-Essen. For the general aims of cNEUPRO, (see
Box 1). The consortium consists of 14 academic partners
(University of Duisburg-Essen, Centre Hospitalier Universi-
taire de Montpellier, Sahlgrenska Academy at the University
of Gothenburg, VU University Medical Center, University
of Ulm, University of Newcastle upon Tyne, University of
Aveiro, University of Szeged, University of Perugia, Ruhr-
University Bochum, Heinrich Heine University of Duessel-
dorf, University of Eastern Finland Kuopio, Institut de la
Sant´ e et de la Recherche M´ edicale, University of Erlangen) asInternational Journal of Alzheimer’s Disease 3
The general AIMS of cNEUPRO are:
(i) Detection of new biomarkers for the early, predictive and diﬀerential diagnosis of neurodegenerative
diseases in CSF and blood
(ii) Development of new diagnostic assays for the early and predictive diagnosis of neurodegenerative
diseases in CSF and blood
(iii) Contribution to the standardization of neurochemical dementia diagnosis
(iv) Establishment of two neurochemical dementia diagnosis reference-centers in Hungary and Portugal
Box 1: General aims of cNEUPRO.
well as four small to medium enterprises. (Matrix Advanced
Solutions Germany GmbH, MicroDiscovery GmbH, Prota-
gen, BioGenes GmbH).
cNEUPRO integrates almost all diﬀerent levels of
biomarker research: the primary phase involves the com-
prehensive clinical characterization of patients and stan-
dardized sample-acquisition and handling by specialized
geriatric psychiatrists and neurologists. These samples are
subsequently used in the search for candidate biomarkers,
their biochemical identiﬁcation by mass spectrometry, and
their reassessment in a second, independent set of high
quality samples. Finally, the identiﬁed biomarkers will be
integrated into novel prototype assays (Figure 1).
The research within cNEURPO concentrates on indi-
viduals diagnosed with MCI at baseline who subsequently
either developed AD, other dementias, or who did not
progress to dementia. As the samples had been taken at
baseline, clinical information obtained during follow-up
allows the identiﬁcation of predictive biomarker candidates
retrospectively. In addition, clinical samples from patients
with early AD at baseline or other dementias in the early
stages are also included in the analysis.
In the search for new biomarker candidates in CSF or
blood, hypothesis-free proteomic approaches such as urea-
based gel electrophoresis, Multidimensional liquid chro-
matography, combined with two-dimensional diﬀerential
gel electrophoresis (2D-DIGE), several mass spectrometric
methods (e.g., SELDI-TOF, MALDI-TOF, nanoLC-MALDI-
TOF/TOF, nanoLC-ESI, nanoLCQFTMS), and array-based
methodsareconducted.Additionally,speciﬁcandpotentially
interesting molecules are studied in detail in the sense
of “hypothesis-driven approaches”. The most promising
biomarker candidates will be selected with the aid of
biostatistical tools. Where applicable, published information
in terms of the biological function or a possible role of
selected candidates in the pathophysiology of AD will also
be considered. The selected candidates will be reassessed
with a further independent high quality clinical sample of
age- and sex-matched patients and controls and with assays
allowing for intermediate sample throughput and quantita-
tive comparisons. For those biomarker candidates that can
be successfully validated, cNEUPRO will devise novel poly-
and monoclonal antibodies. Finally the biomarkers will be
integrated into novel ELISA-type assays and, if appropriate,
in Multiplex-Assays.
An essential prerequisite for a successful multicenter
biomarker-discovery study is the standardization of the
Clinical phenotyping and diagnostic SOP
Preanalytics and preanalytic SOP
High quality CSF and blood samples
CSF Blood
Biomarker candidates
Biomarker
Antibody generation
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Figure 1: Workﬂow within the project.
clinical diagnostics, the preanalytical sample handling proce-
dures,andthemeasurementsoftheknownbiomarkerstotal-
tau, phospho-tau, and Aβ1-42 in CSF. To this end, two neu-
rochemical dementia diagnosis reference centers in Hungary
and Portugal are currently being established, and European
standard operating procedures for clinical diagnostics and
preanalytical sample handling have been deﬁned.
3. CurrentStateandFirstResults of cNEUPRO
3.1. Neurochemical Dementia Diagnosis-Reference Center in
Hungary Launched. In Hungary, 42 Dementia Centers are
responsible for the diagnosis and treatment of demented4 International Journal of Alzheimer’s Disease
Diagnostic standard operating procedure
(i) AD is diagnosed according to the NINCDS-ADRDA criteria [27].
(ii) DLB is diagnosed according to the criteria of McKeith [28].
(iii) VaD is diagnosed according to the NINCDS-AIREN criteria [29].
(iv) FTLD is diagnosed according to the consensus criteria of Neary [30].
(v) CJD is diagnosed according to the WHO criteria (Geneva 1998).
(vi) CDR is used for staging of Dementia [31].
(vii) MMSE is used for grading of dementia [32].
(viii) A follow-up of two years must be retrievable.
(ix) Additional neuropsychological testing is desirable but not mandatory.
(x) A CT or MRI scan must be available.
(xi) The ApoE genotype should be determined.
(xii) CSF should be obtained and the concentration of Aβ1-42, tau and phospho-tau should be determined.
Box 2: Diagnostic standard operating procedure. AD = Alzheimer’s Disease, DLB = Dementia with Lewy-bodies, VaD = Vascular Dementia,
FTLD = frontotemporal lobar degeneration, CJD = Creutzfeldt-Jacob Disease, CDR = Clinical Dementia Rating Scale, MMSE = Mini Mental
Status Examination. References in the box: [27–32].
patients. Before 2009, the CSF analysis of Aβ1-42, total-tau,
and phospho-tau to support dementia diagnostics was not
possible for these centers. As one of the aims of cNEUPRO,
the ﬁrst reference center for neurochemical dementia diag-
nosis in Hungary was launched in Szeged. With the support
ofthecNEUPROconsortium,state-of-the-artdiagnosticand
methodological standards have been implemented, and the
center takes part in an ongoing quality control program
organized by Kaj Blennow from Sahlgrenska University
Hospital, M¨ olndal, Sweden. During its ﬁrst twelve months of
operation, the neurochemical dementia diagnosis reference
center in Szeged has received a total of 54 CSF samples
from 14 diﬀerent Dementia Centers in Hungary. This
neurochemical dementia diagnosis center will now try to
provide its service to further Dementia Centers in Hungary
and to start collecting samples for scientiﬁc purposes.
3.2. Diagnostic and Preanalytical Standard Operating Proce-
dures. Due to substantial intercenter variations, the reported
accuracy of CSF biomarkers is considerably lower in mul-
ticenter studies than in single center surveys [22–24]. To
this end, a multicenter study, supported by cNEUPRO,
provides guidance on how to establish, validate, and audit
CSF tau cutoﬀ values using an unbiased, two-stage mul-
ticentre strategy [25]. Furthermore, a hands-on workshop
was organized by members of the cNEUPRO consortium
(paper submitted to the same issue of IJAD). The aim of the
workshop was to assess the diﬀerences in assay procedures
as potential sources of error. During this workshop, 14
groups simultaneously performed the Aβ1-42, total-tau, and
phospho-tau assays according to the guidelines of the
manufacturer. At least 23 items in assay procedures were
identiﬁed that varied between the laboratories, including
procedures for washing, pipetting, incubation, ﬁnishing,
and sample handling. Thus, even if centers use the same
assays for Aβ1-42, total-tau, and phospho-tau measurement
on a regular basis, they do not uniformly adhere to the
procedures recommended by the manufacturer. The results
of the workshop stress the importance of standardization
of assay protocols. To facilitate biomarker research on a
multicenter level, standard operating procedures for the
clinical diagnosis and the preanalytical sample handling have
been deﬁned by the cNEUPRO consortium (Boxes 2 and 3).
The standard operating procedures for sample acquisition,
handling, and storage deﬁned by cNEUPRO meet the quality
standards required for proteomic studies in CSF [19]a n d
are in agreement with the recently published guidelines for
CSF collection and biobanking from the BioMS-eu network
[26].
3.3. Investigated CSF Biomarker Candidates for AD Related
to Amyloid Precursor Protein (APP) Processing and Tau
Pathology. In the last decade, the levels of Aβ peptides and
tau proteins in CSF have gained increasing importance in
supporting the clinical diagnosis of AD [10, 33]. As no
single marker alone allows for a diagnosis with the desired
accuracy, several combinations of CSF-biomarkers (Aβx-42,
Aβx-40, total-tau, phospho-tau) have been proposed [12].
For these markers, a diagnostic accuracy of up to 94%
has been achieved in single center studies [12]. Within
cNEUPRO, Welge et al. reported a sensitivity and speciﬁcity
of 88% in the discrimination of AD subjects from other
dementias and from elderly depressed individuals with cog-
nitive complaints, by combining the measurement of Aβ1-40,
Aβ1-38, and phospho-tau [34]. With the use of MALDI-TOF
mass-spectrometry for the study of CSF samples from AD
patients, anoxidized formofAβ1-40 (Aβ1-40
ox) wasidentiﬁed.
Quantiﬁcation by SDS-PAGE/western immunoblot revealed
elevated Aβ1-40
ox levels in patients with AD as compared
to probable vascular dementia and controls [35]. Taken
together, these pilot studies suggest that besides Aβ1-42,
additional variants of Aβ peptides may turn out to be
speciﬁcally altered in AD patients.
Although combinations of these CSF biomarkers were
reported to have a high predictive value in single-center
studies, their application in multicenter-studies is hampered
by relatively high intercenter variations. In an associated
multicenterstudy,including750patientswithMCIwhowereInternational Journal of Alzheimer’s Disease 5
Preanalytical standard operating procedure for CSF:
(i) Cerebrospinal ﬂuid (CSF) is collected by lumbar puncture (LP). Ventricular CSF can also be included
but should be clearly labelled as such.
(ii) CSF is collected in polypropylene tubes.
(iii) A standardised volume (10–12mL) is collected.
(iv) Samples contaminated with more than 500 red blood cells/μL should not be included.
(v) Collected CSF is centrifuged at approximately 1,000–2,500xg at +4◦Co rr o o mt e m p e r a t u r ef o r1 0
minutes within 1 hour after the sampling.
(vi) The supernatant is pipetted oﬀ, gently mixed to avoid possible gradient eﬀects and aliquoted in
portions in polypropylene tubes.
(vii) The samples are stored at −80◦C without having been thawed and re-frozen.
Preanalytical standard operating procedure for serum and plasma:
(i) Serum and plasma are collected by vein puncture.
(ii) Plasma is collected into polypropylene tubes containing EDTA.
(iii) Serum is collected into polypropylene tubes without additives.
(iv) Collected blood samples are centrifuged at approximately 1,000–2,500xg at +4◦Co rr o o m
temperature for 15 minutes within 2 hour after the sampling.
(v) The supernatant is pipetted oﬀ, gently mixed to avoid possible gradient eﬀects and aliquoted in
portions in polypropylene tubes.
(vi) The samples are stored at −80◦C without having been thawed and re-frozen.
Box 3: Preanalytic standard operating procedures for CSF and blood.
followed for at least two years, the conversion to AD could be
predictedwithasensitivityof83%andaspeciﬁcityof72%by
the ratio of Aβ1-42/phospho-tau and total-tau. These values
aresubstantiallylowerthanthoseseeninseveralsinglecenter
studies[24].Thehighestintercentervariationswerereported
for Aβ1-42.A st h i si sp r o b a b l yd u et oi t sh i g hp o t e n t i a lt o
form aggregates and to stick to test tubes, alternative markers
related to APP processing have been investigated within
cNEUPRO. In an associated multicenter study, sAPPα and
sAPPβ, two proteins secreted in the CSF after the α-o rβ-
secretase cleavage of APP, were assessed in 188 patients with
MCI or mild to moderate AD. In previous studies, sAPPα
andsAPPβwerefoundtobeunchanged[36,37]ordecreased
[38–40]intheCSFofADpatients.WithincNEUPRO,sAPPα
and sAPPβ levels in CSF of MCI and AD patients with
elevated total-tau and reduced Aβ1-42 CSF concentrations
were compared to those from patients without a respective
CSF biomarker proﬁle. Both were found to be higher in the
CSF from patients with an AD-indicative biomarker proﬁle
[41]. Taken together, these results suggest that sAPPα and
sAPPβ may be indicators of altered APP expression and/or
metabolism. Reports on their value as candidate biomarkers
are however so far contradictory.
In a diﬀerent study which was supported by cNEUPRO,
six novel N-terminal APP-fragments with molecular masses
of approximately 12kDa and starting at amino acid 18 of the
APPsequenceweredetectedinCSFbymassspectrometry.In
a subsequent small pilot study, six of six AD patients and ﬁve
of ﬁve controls could be classiﬁed correctly by the combined
evaluation of ﬁve of the six fragments [42]. Additionally,
Immuno-MS analysis of CSF has led to the detection of
eleven novel APP fragments, which begin N-terminally to
the β-secretase cleavage site, and end one amino acid before
the proposed α-secretase cleavage site (APP/Aβ peptides)
[43]. Interestingly, seven of the twelve APP/Aβ peptides were
signiﬁcantly upregulated in AD [43].
3.4. CSF-Biomarker Candidates for AD Investigated within
cNEUPRO, Which Are Not Related to APP Processing or Tau
Pathology. One of several kinases that have been suggested
to be involved in the abnormal hyperphosphorylation of
tau is the MAP-kinase ERK1/2. In a methodological pilot
study, ERK 1/2 and its doubly phosphorylated, activated
form have been detected in a small number of CSF samples
from patients with AD, MCI, and frontotemporal lobar
degeneration(FTLD)[44].ToevaluatetheusefulnessofERK
1/2 as a potential novel CSF biomarker, ERK1/2 levels in CSF
arecurrentlybeingstudiedinatotalof110CSFsamplesfrom
partners within the consortium with a chemiluminescent 96
well assay format.
In accordance with a previous report [45], research
within cNEUPRO found glial ﬁbrillary acidic protein
(GFAP), a marker for astrogliosis, to be increased in CSF of
AD and sporadic Creutzfeldt-Jacob Disease (sCJD) patients.
CSF samples of 18 AD patients, 22 sCJD cases, and 18
from nondemented controls were analyzed with the use
o fac o m m e r c i a l l ya v a i l a b l eE L I S A .I nA D ,ar e m a r k a b l e
elevation in CSF GFAP levels with no overlap to controls was
observed. Although a signiﬁcant increase in GFAP could be
observed in CJD aswell,this wasnot aspronounced asin AD
[46]. Consequently GFAP might have some additive value as
part of a biomarker supported diagnosis, although it lacks
speciﬁcity for AD.
Chronic inﬂammation associated with oxidative and
nitrosative stress is another aspect which is considered to
be important in the pathophysiology of AD [47]. The most
common protein markers of oxidative and nitrosative stress
are protein-bound carbonyls and 3-nitrotyrosine [48]. An6 International Journal of Alzheimer’s Disease
increased oxidation of certain proteins and an increased
concentrationof3-nitrotyrosine havebeenreported intissue
[49] and CSF [50–52] of AD patients, but there is also
contradictory data indicating no diﬀerence between AD
and controls [53]. In a study conducted by members of
the cNEUPRO consortium, where the concentrations of 3-
nitrotyrosineandtotalproteincarbonylationweremeasured,
no change was found in CSF of AD patients [48]. Yet,
slightly reduced levels of protein carbonyls were detected in
ApoE-ε4 carriers as compared to ApoE-ε4 noncarriers [48].
These results suggest that the concentrations of total protein
carbonyls and 3-nitrotyrosine are at this stage not suitable
to monitor the chronic inﬂammatory processes related
to AD.
3.5. Investigated CSF Biomarkers for Other Neurodegenerative
Diseases. In addition to promoting the early and predictive
diagnosis of AD, cNEUPRO is also dedicated to search for
new biomarkers to support the diagnosis of other neurode-
generative diseases such as sCJD, FTLD, vascular dementia
(VaD), Dementia with Lewy bodies (DLB), Parkinson’s
Disease (PD), and Parkinson’s Disease Dementia (PDD).
Two-dimensional diﬀerential gel electrophoresis (2D-
DIGE) followed by MALDI-TOF mass-spectrometry indi-
cated that CSF from patients with sCJD diﬀered from CSF
from patients with other neurological deﬁcits on the basis
of several protein spots. Among these, several previously
identiﬁed surrogate markers of sCJD such as 14-3-3 protein,
neuron-speciﬁc enolase, and lactate dehydrogenase were
identiﬁed. Additionally, an unidentiﬁed protein of 85kDa
was found to be signiﬁcantly increased in sCJD patients [54].
In a separate cNEUPRO investigation, SELDI-TOF mass
spectrometry was applied in the analysis of CSF from 32
sCJD patients, 32 controls, and 31 patients with other
dementias. Ubiquitin, an 8.6 kDa protein involved in protein
degradation, was found to be elevated in the CSF of sCJD
cases. This could be conﬁrmed by reassessment with western
immunoblots. In the study population, the accuracy of
a biomarker-based classiﬁcation of the samples could be
signiﬁcantly improved by including Ubiquitin in addition to
tau, and 14-3-3 protein [55]. This ﬁnding is in accordance
withseveralpreviousreportswhereUbiquitinwasalsofound
to be elevated in the CSF of sCJD patients [56]. As there is
also evidence for altered levels of CSF Ubiquitin in AD [57–
59]andvasculardementia[60],itseemsthatthisobservation
is related to neurodegenerative processes in general and
not to a speciﬁc disease. Yet, in the Steinacker study CSF
Ubiquitin levels in sCJD were higher than those in other
dementias [55]. Therefore, Ubiquitin may still be a good
biomarker for sCJD if, as with tau protein [61], disease-
speciﬁc cut-oﬀ values are applied.
S100B, another astroglial marker, may also be useful to
supportthediagnosisofsCJD.WithincNEUPRO,S100Bwas
measured in 54 CSF samples from patients with sCJD, AD,
and control patients with the use of a commercial ELISA.
Supporting previous ﬁndings [62, 63], S100B was shown
to be highly elevated in sCJD with no overlap to the other
groups [46]. Others have found elevated S100B in familial
CJD cases [64], but also in CSF [65]a n ds e r u m[ 66]o fA D
patients. These ﬁndings suggest that more attention might
be paid to the use of astroglial markers in supporting the
diﬀerential diagnosis of dementias [46].
With respect to FTLD, cNEUPRO found elevated mean
levels of the TAR DNA-binding Protein 43 (TDP-43) and
reduced Aβ1-42 levels [67, 68]. In line with the reported
increased gene expression of TDP-43 in brain tissues [69],
elevated 45kDa TDP-43 levels were found in the CSF of
12 patients with FTLD as compared to 13 nondemented
controls by western-immunoblot [67].
In the same sample, the assessment of diﬀerent Aβ
peptide species, sAPPα and sAPPβ,b ye l e c t r o c h e m i -
luminescence-based multiplex assays indicated no signiﬁ-
cant diﬀerence for sAPPα and sAPPβ between the groups.
However, reduced Aβ1-42 levels were found in FTLD [68].
These ﬁndings are supported by several earlier studies which
found CSF-levels of Aβ1-42 in FTLD to be lower than in
nondemented controls and higher than in AD [70–73].
However,therearealsocontradictorypublications,regarding
levels of Aβ species which did not ﬁnd reduced CSF Aβ1-42
concentrations in FTLD [74, 75]. Although TDP-43 and
fragments of APP processing are currently not suitable as
biomarkers because of a large overlap between the diﬀerent
diagnostic groups, these ﬁndings may still reﬂect aspects
relevant for understanding the pathophysiology of these
disorders.
In an associated study focussed on the biomarker
supported diﬀerential diagnosis of AD, PD, PDD, and DLB,
CSF Aβ1-42, total-tau, and phospho-tau were measured in
the CSF of a total of 80 patients. Although some signiﬁcant
diﬀerences in the average biomarker measurements were
found between the groups, only AD patients could be
eﬀectively diﬀerentiated from patients with other dementias
by phospho-tau. For Aβ1-42, total-tau, and phospho-tau, a
large overlap between the other neurodegenerative diseases
was observed. Interestingly, only in DLB were Aβ1-42 and
total-tau found to correlate with the duration and the
severity of dementia [76]. Consequently, more and better
biological markers are needed to support the diﬀerential
diagnosis of these dementias [77].
A marker with a potential speciﬁcity for synucleinopa-
thies may be the lysosomal hydrolase β-glucocerebrosidase.
In addition to a previous report linking a reduced activity
of β-glucocerebrosidase to PD [78], a reduced activity of
β-glucocerebrosidase was speciﬁcally found in DLB within
cNEUPRO. In CSF from nondemented controls, patients
with AD or FTLD, no diﬀerences in β-glucocerebrosidase
activity were found. In contrast, the activity of α-
mannosidase, another lysosomal hydrolase, was found to be
signiﬁcantly reduced in all investigated neurodegenerative
diseases as compared to controls [79]. In order to support
the hypothesis that CSF β-glucocerebrosidase activity might
be a novel CSF biomarker of synucleinopathies, the data
need to be conﬁrmed in larger studies.
3.6. Investigated Blood-Biomarker Candidates Related to APP
Processing. Several recent studies aimed at identifying AD
biomarkers in blood were speciﬁcally targeted at determina-
tion of Aβ peptides in blood plasma or serum [20].International Journal of Alzheimer’s Disease 7
Within a cNEUPRO associated substudy of the German
Kompetenznetz Demenzen (http://www.kompetenznetz-
demenzen.de/), Aβ1-40 and Aβ1-42 were assessed in blood
plasma from 257 individuals with multiplexing technology
on the Luminex platform. A statistically signiﬁcant decrease
oftheAβ1-42/1-40 ratiowasfoundintheplasmaofthepatients
with early AD and MCI of AD type whose clinical diagnoses
were backed up by corresponding ﬁndings in the CSF [80].
Moreover, the cNEUPRO associated French “Three-City
study” found that a reduction of the ratios Aβ1-42/Aβ1-40 as
well as Aβx-42/Aβx-40 was associated with an increased risk
of developing dementia within the next two years [81]. In
contrast, several other published studies have not reported
signiﬁcant diﬀerences in Aβ peptide concentrations in
blood plasma between AD patients and controls [82–84].
In summary, there is no deﬁnitive conclusion as to whether
plasma Aβ reﬂects the changing level of central amyloid
[20]. Due to the substantial interindividual variations and
a large overlap between the diagnostic groups, measuring
the individual concentrations of Aβ peptides in plasma is
not suitable to support the clinical diagnosis of diﬀerent
dementia disorders. However, there is preliminary evidence
that speciﬁc forms of Aβ peptides in plasma prove to be
helpful in the diﬀerential diagnosis of AD and other demen-
tias. In a retrospective pilot study which was supported by
cNEUPRO, vascular dementia could be diﬀerentiated with
a sensitivity and speciﬁcity of >80% from other dementias
and depressive controls by the ratio of Aβ1-38/Aβ1-40 [85].
Currently, highly sensitive assays for the detection of Aβ
peptides in blood and CSF are available for Aβx-38,A βx-40,
andAβx-42.ForadetailedanalysisofadditionalvariantsofAβ
peptides in blood plasma, a highly sensitive two-dimensional
gel separation method was established within cNEUPRO.
Using this method, at least 30 diﬀerent Aβ peptides were
observed [86]. Semiquantitative analysis revealed that the
peptides Aβ1-40 and Aβ1-42 accounted for less than 60% of
all Aβ peptides that were detected by the speciﬁc antibody
that was used in this study. At least 10% of the detected
Aβ peptides appear to be N-terminally truncated [86]. One
possible source of these N-terminally truncated Aβ peptides
detected in human plasma is mononuclear phagocytes.
Cultures of human mononuclear phagocytes were shown
to secrete complex Aβ peptide patterns characterized by a
high proportion of N-terminally truncated variants [87].
Furthermore, the secretion of Aβ peptides from human
mononuclear phagocytes was diﬀerentially regulated in
response to cell culture conditions [87] and was elevated in
cell cultures of mononuclear phagocytes from AD patients as
compared to controls [88]. Additional work is under way to
evaluate several N- and C-terminally truncated Aβ peptides
in plasma as potential biomarkers for AD.
3.7. Currently Ongoing Research in cNEUPRO. The iden-
tiﬁcation of valid biomarkers in blood is highly desirable
because they have the advantage of being easily accessible.
The search for potential biomarker candidates in plasma
or serum is complicated by the presence of a number of
highly abundant proteins. These proteins which are believed
to have only small diagnostic potential make up about 90%
of the whole plasma proteome [89]. As a ﬁrst step towards
biomarker discovery in serum, it was shown that the deple-
tion of 12 high abundant serum proteins by immuno aﬃnity
chromatography columns resulted in an increased number
of detected peaks by subsequent analysis with SELDI-TOF
mass spectrometry [90]. In contrast, CSF proteomics for
biomarker discovery in neurodegenerative diseases is partic-
ularly attractive because of the proximity of CSF to the brain.
Again,theremovalofhighlyabundantproteinsresultedinan
improved detection of low abundant CSF proteins including
brain-derived proteins. Additional separation procedures
were introduced to account for the large dynamic range
of the expression levels and to simplify the analysis of
proteolytically generated peptides by mass spectrometry. For
a comparative analysis of individual clinical samples and
for a relatively in-depth search for potential novel biomark-
ers, reproducibility is an absolute requirement. Therefore,
diﬀerent multiaﬃnity depletion methods followed by gel-
nanoLC-MS/MS and spectral counting have been evaluated
for the in-depth, label-free quantitative analysis of CSF.
Depletion in spin-ﬁlter format, coupled to gel-LC-MS/MS,
provided a robust method that yielded ∼800 CSF proteins
per analyzed sample, with acceptable reproducibility of
protein identiﬁcation (71%–74% in technical replicates) and
quantiﬁcation(17%–18%CVonspectralcounts).Tocontrol
for reproducibility, the same workﬂow was implemented in
twoseparatelaboratorieswithincNEUPRO.Thisproteomics
approach was subsequently applied in both laboratories to
the independent analysis of two separate cohorts of 20
individual CSF samples each. In both cohorts the patients
wereclinicallydiagnosed,andCSFwastakenaccordingtothe
cNEUPRO standard operating procedures. Both discovery
sets of samples included CSF samples from ﬁve control
subjects, from ﬁve subjects with mild cognitive impairment
without conversion to AD, from ﬁve patients with mild
cognitive impairment with conversion to AD within the
follow-up of 2 years, and ﬁve patients with AD. Both datasets
contained ∼1100 identiﬁed proteins with a total of ∼1600
unique CSF proteins in the common dataset and an overlap
of ∼500 between the two laboratories. The biostatistical
analysis is currently on-going to select the most promising
candidates for a reassessment by targeted mass spectrometry
and antibody-based methods in a larger set of samples.
4. Conclusion
Within the ﬁrst two years, cNEUPRO conﬁrmed sAPP,
various Aβ peptide variants, GFAP, S100B, and ubiquitin
as biomarker candidates known from previous studies.
Additionally, further APP fragments were discovered and
TDP-43 as well as β-glucocerebrosidase and ERK 1/2 were
proposed as potential novel candidate biomarkers for the
early and diﬀerential diagnosis of neurodegenerative diseases
(Table 1). Because of the high complexity of the blood
proteome and probably because of its distance from brain
pathology, novel biomarkers in serum or plasma are still
elusive. To promote biomarkers in support of the clinical
diagnosis of neuropsychiatric disorders in Europe, cNE-
UPRO devised European standard operating procedures8 International Journal of Alzheimer’s Disease
Table 1: List of candidate biomarkers investigated in the context of cNEUPRO. CON: control patient, AD: Alzheimer’s Disease, OD: other
dementia,VaD:vasculardementia,MCI:Mildcognitiveimpairment,sCJD:sporadicCreutzfeldt-JacobDisease,FTLD:Frontotemporallobar
degeneration, ALS: Amyotrophic Lateral Sclerosis, DLB: Dementia with Lewy bodies.
Biomarker candidate Context/Function Method Patients n Result Ref.
Investigated CSF candidate biomarkers for AD related to APP processing
Aβ1-42/1-38 ratio APP processing ELISA/MSD
CON 30
AD 44 Reduced in AD [34]
OD 87
Aβ1-40
ox APP processing Western blot
CON 30
AD 30 Elevated in AD [35]
VaD 37
sAPP APP processing Luminex
MCI 81 Elevated sAPPα/β in
AD 69 patients with elevated [41]
OD 38 tau and reduced Aβ1-42
APP/Aβ APP processing LC-MS CON 3 Elevated in AD [43]
AD 3
12kDa sAPP APP processing
LC-FTICR-MS CON 6 Elevated in AD [42]
AD 5
Western blot CON 6 Elevated in AD [42]
AD 6
Investigated CSF candidate biomarkers for AD not related to APP processing
GFAP Marker for astrogliosis ELISA
CON 12
AD 18 Elevated in AD [46]
sCJD 22
Total protein Neuro-inﬂammation ELISA CON 18 No diﬀerence between [48]
carbonylation AD 22 AD and CON
3-nitrotyrosine Neuro-inﬂammation ELISA CON 18 No diﬀerence [48]
AD 22 between AD and CON
ERK 1/2 MAP-Kinase
MCI 9
western blot/electrochemi-
luminescence AD 4 Pilot study, no statistics [44]
FTLD 2
Investigated CSF candidate biomarkers for other dementias
S100B Marker for astrogliosis ELISA
CON 12
AD 18 Elevated in sCJD [46]
sCJD 22
TDP-43 DNA binding protein Western blot
CON 13
FTLD 12 Elevated in FTLD [67]
ALS 15 and ALS
ALS+FTLD 9
85 kDa protein Unknown 2D-DIGE/MALDI-TOF
CON 6
AD 24 Elevated in sCJD [54]
sCJD 36
DLB 6
Ubiquitin Protein degradation LC-MS/WB
CON 32
sCJD 32 Elevated in sCJD [55]
OD 31
α-Mannosidase Lysosomal Hydrolase Enzyme activity assay
CON 23
AD 20 Reduced in all [79]
FTLD 20 dementias
DLB 17International Journal of Alzheimer’s Disease 9
Table 1: Continued.
Biomarker candidate Context/Function Method Patients n Result Ref.
β-Glucocerebrosidase Lysosomal
Hydrolase Enzyme activity assay
CON 23
AD 20 Reduced in DLB [79]
FTLD 20
DLB 17
for preanalytical sample handling and established a neuro-
chemical dementia diagnosis reference center in Hungary.
cNEUPRO has now started to select the most promising
biomarker candidates from two proteomic studies within
cNEUPRO and to reassess the most promising biomarker
candidates with larger sample size and independent methods
to ﬁnally integrate them into novel prototype assays.
To increase the accuracy of a biomarker-based diagno-
sis, biomarkers in body-ﬂuids have been combined with
other biological markers such as structural and functional
neuroimaging and neuropsychological testing [91]. Whether
the new biomarker assays which will be developed within
cNEUPRO will be useful in such a multimodal diagnostic
workup remains to be elucidated.
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